1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)
    Meeting Abstract

    O'Cearbhaill, R.; Sill, M.; Duong, H.; Waggoner, S.; Grisham, R.; Backes, F.; Mannel, R.; Tanyi, J.; Powell, M.; Mathews, C.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • Ubamatamab (MUC16XCD3 bispecific antibody) with or without cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 clinical and biomarker results
    Meeting Abstract

    Liu, J.; O'Malley, D.; Van Nieuwenhuysen, E.; Moore, K.; Hamilton, E.; Yeku, O.; Bouberhan, S.; Hou, J.; Schröder, D.; Wang, B.; more...
    International Journal of Gynecological Cancer (2023)

    Fulltext@MSK | Save
  • Associations between cancer predisposition mutations and clonal hematopoiesis in patients with solid tumors
    Journal Article

    Franch-Expósito, S.; Mehine, M.; Ptashkin, R. N.; Bolton, K. L.; Bandlamudi, C.; Srinivasan, P.; Zhang, L.; Goodell, M. A.; Gedvilaite, E.; Menghrajani, K.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Germline pathogenic variants and genetic counseling by ancestry in patients with epithelial ovarian cancer
    Journal Article

    Sia, T. Y.; Maio, A.; Kemel, Y. M.; Arora, K. S.; Gordhandas, S. B.; Kahn, R. M.; Salo-Mullen, E. E.; Sheehan, M. A.; Tejada, P. R.; Bandlamudi, C.; more...
    JCO Precision Oncology (2023)

    Fulltext@MSK | Save
  • Understanding genomic and social determinants of cancer immunotherapy outcome across ancestry
    Meeting Abstract

    Fong, C. J.; Waters, M.; Pichotta, K.; Jee, J.; Jutagir, D. R.; Ma, D.; Perea-Chamblee, T.; Kim, S.; Arora, K.; Mastrogiacomo, B.; more...
    Cancer Research (2023)

    Fulltext@MSK | Save
  • A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials
    Journal Article

    Kostakoglu, L.; Martelli, M.; Sehn, L. H.; Davies, A.; Trneny, M.; Herold, M.; Vitolo, U.; Hiddemann, W.; Trotman, J.; Knapp, A.; more...
    Ejhaem (2023)

    Fulltext@MSK | Save
  • Treatment outcomes and prognostic factors with lenalidomide, bortezomib, and dexamethasone (RVd) alone versus RVd plus autologous stem cell transplantation (ASCT) in African American (AA) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the DETERMINATION phase 3 trial
    Meeting Abstract

    Houde, C. A.; Khan, A.; Jacobus, S. J.; Hassoun, H.; Anderson, L. D. Jr; Merz, L. E.; Zon, R. L.; Efebera, Y.; Buck, T.; Innis-Shelton, R. D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Practice patterns of transplant centers regarding maintenance treatment post allogeneic hematopoietic cell transplantation in acute myeloid leukemia: A survey on behalf of the EBMT Acute Leukemia Working Party
    Meeting Abstract

    Abou Dalle, I.; Labopin, M.; Khvedelidze, I.; Baron, F.; Brissot, E.; Bug, G.; Esteve, J.; Giebel, S.; Gorin, N. C.; Lanza, F.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes of patients with accelerated/blast-phase MPNs that received allogeneic stem-cell transplant in the current era of myeloid therapies
    Meeting Abstract

    Patel, A. A.; Yoon, J. J.; Johnston, H.; Davidson, M. B.; Viswabandya, A.; Shallis, R. M.; Chen, E. C.; Burkart, M.; Oh, T. S.; Iyer, S. G.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory follicular lymphoma: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Shah, N. N.; Zinzani, P. L.; Wang, M. L.; Nasta, S. D.; Lech-Maranda, E.; Ogawa, Y.; Fakhri, B.; Kuss, B.; Miyashita, K.; Patel, K.; more...
    Blood (2023)

    Fulltext@MSK | Save